• Explore /
  • Poster
  • / Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with <em>BRCA1/2</em> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Abstract Video & Slides Poster

Authors

null

Charles Drescher

Swedish Cancer Institute, Seattle, WA

Charles Drescher , Michael Rothe , Pam K. Mangat , Elizabeth Garrett-Mayer , Deepti Behl , Eugene R Ahn , Tareq Al Baghdadi , R. Wendel Naumann , Maria C Bell , Charles A. Leath III, Timothy Lewis Cannon , Olatunji B. Alese , Gina N. Grantham , Abigail Gregory , Dominique C. Hinshaw , Susan Halabi , Richard L. Schilsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02693535

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5548)

DOI

10.1200/JCO.2023.41.16_suppl.5548

Abstract #

5548

Poster Bd #

243

Abstract Disclosures

Similar Posters

First Author: Gordan Srkalovic

First Author: Katherine E Poruk

First Author: Andreas Seeber

First Author: Sherri Z. Millis